Cargando…
Developments in Glycopeptide Antibiotics
[Image: see text] Glycopeptide antibiotics (GPAs) are a key weapon in the fight against drug resistant bacteria, with vancomycin still a mainstream therapy against serious Gram-positive infections more than 50 years after it was first introduced. New, more potent semisynthetic derivatives that have...
Autores principales: | Blaskovich, Mark A. T., Hansford, Karl A., Butler, Mark S., Jia, ZhiGuang, Mark, Alan E., Cooper, Matthew A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952257/ https://www.ncbi.nlm.nih.gov/pubmed/29363950 http://dx.doi.org/10.1021/acsinfecdis.7b00258 |
Ejemplares similares
-
Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
por: Cheng, Mu, et al.
Publicado: (2014) -
Polishing the tarnished silver bullet: the quest for new antibiotics
por: Blaskovich, Mark A.T., et al.
Publicado: (2017) -
Institutional profile: Community for Open Antimicrobial Drug Discovery – crowdsourcing new antibiotics and antifungals
por: Desselle, Mathilde R, et al.
Publicado: (2017) -
Impact of the new membrane-targeting lipoglycopeptide antibiotic MCC5145 on the treatment of bacteremic pneumococcal pneumonia in mice
por: Ogunniyi, Abiodun D., et al.
Publicado: (2023) -
Glycopeptide antibiotics /
Publicado: (1994)